Technology | Stent Grafts | March 07, 2016

Gore Excluder Iliac Branch Endoprosthesis Gains FDA Approval

All-in-one system preserves iliac artery blood flow in patients with iliac or aortoiliac aneurysms

Gore Medical, Excluder Iliac Branch Endoprosthesis, FDA approval

Image courtesy of Gore Medical

March 7, 2016 — At the Houston Aortic Symposium, W. L. Gore & Associates, Inc. (Gore) announced the U.S. Food and Drug Administration (FDA) approval of the Gore Excluder Iliac Branch Endoprosthesis (IBE). The approval makes it the first off-the-shelf aortic branch device approved in the United States and the only device indicated for the endovascular treatment of common iliac artery aneurysms or aortoiliac aneurysms

The device is a complete, fully engineered system (Gore-designed iliac branch and internal iliac components), which received CE Mark in 2013. The device is used in conjunction with the Gore Excluder AAA (abdominal aortic aneurysm) Endoprosthesis to isolate the common iliac artery from systemic blood flow and preserve blood flow in the external iliac and internal iliac arteries. The device is built on Gore’s technology platform and designed using the same durable, expanded polytetrafluoroethylene (ePTFE) graft and nitinol stent material.

The IBE offers an all-in-one system with improved outcomes for the treatment of iliac artery aneurysms while preserving flow to the iliac arteries, which is the recommended treatment by vascular surgery societies to sustain patient quality of life. Preservation of blood flow in the internal iliac arteries is found to avoid pelvic flow disruption and reduce the rate of buttock claudication, sexual dysfunction, and colonic ischemia.

“Historically, options to preserve flow to the internal iliac arteries during endovascular aneurysm repair were very limited despite the involvement of the iliac arteries in about 25 percent of AAA cases,” said Darren Schneider, M.D., chief of vascular and endovascular surgery and associate professor of surgery at Weill Cornell Medicine and principal investigator for the national Gore Excluder Iliac Branch Device Clinical Study. “However, through our research and the subsequent FDA approval, physicians now have a new therapeutic option to preserve pelvic perfusion in order to improve clinical outcomes and maintain patient quality of life.”

The IBE system provides a treatment range of 6.5-13.5 mm for the internal iliac arteries, and a treatment range of 6.5-25 mm for the external iliac arteries. The delivery profile of the loaded catheter allows the use of a 16 Fr introducer sheath for the iliac branch component, and a flexible 12 Fr, reinforced introducer sheath for the internal iliac component.

The Gore Eexcluder Iliac Branch Device Clinical Study — a prospective, multicenter, non-randomized, single-arm study designed to assess the safety and effectiveness of the IBE in treating common iliac artery aneurysms or aortoiliac aneurysms — completed enrollment in February 2015. A total of 62 patients received the device, which met the FDA required enrollment of 60 patients.  The trial also enrolled an additional 32 patients through continued access (as of Feb. 15, 2016), which expanded treatment options to allow for bilateral placement of the IBE in addition to unilateral IBE device placement, which was evaluated in the primary enrollment. 

For more information: www.goremedical.com

Related Content

FDA Grants Breakthrough Device Designation for Valiant Thoracoabdominal Aortic Aneurysm Stent Graft
News | Stent Grafts | October 09, 2019
Medtronic plc announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA...
PQ Bypass Granted IDE Approval to Start TORUS SFA Stent Graft Pivotal Study
News | Stent Grafts | October 08, 2019
PQ Bypass Inc. announced it has received full approval of its investigational device exemption (IDE) trial of the...
First U.S. Patient Receives Gore Tag Conformable Thoracic Stent Graft With Active Control
News | Stent Grafts | July 10, 2019
W. L. Gore & Associates Inc. (Gore) announced the first U.S. implant of the Gore Tag Conformable Thoracic Stent...
Gore Receives FDA Approval for Gore Tag Conformable Thoracic Stent Graft
Technology | Stent Grafts | May 15, 2019
W. L. Gore & Associates Inc. (Gore) announced the U.S. Food and Drug Administration (FDA) has granted regulatory...
Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028
News | Stent Grafts | February 14, 2019
Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through...
Medtronic Receives FDA Approval for Valiant Navion Thoracic Stent Graft System
Technology | Stent Grafts | February 07, 2019
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for the Valiant Navion thoracic stent...
Endologix Ends Unrestricted Sales and Use of Nellix System
News | Stent Grafts | January 07, 2019
January 7, 2019 — Endologix Inc.
Endologix Reports Positive One-Year Results From the Ovation LUCY Study
News | Stent Grafts | July 16, 2018
Endologix Inc. announced one-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for...
FDA Committee Votes in Favor of Incraft AAA Stent Graft System
News | Stent Grafts | June 13, 2018
Cardinal Health announced that its Incraft Abdominal Aortic Aneurysm (AAA) Stent Graft System has received a favorable...
First Patient Enrolled in Gore Excluder Investigational Study
News | Stent Grafts | January 08, 2018
January 8, 2018 — W. L. Gore & Associates Inc.